<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468376</url>
  </required_header>
  <id_info>
    <org_study_id>GLU-00-2010-1</org_study_id>
    <nct_id>NCT01468376</nct_id>
  </id_info>
  <brief_title>GLU-xx Formulations in Individuals With Impaired Glucose Tolerance</brief_title>
  <official_title>An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor company was acquired and new owner chose not to proceed with clinical study&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GLU-xx formulations</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>GLU-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLU-06</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-01</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-02</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-03</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-04</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-05</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GLU-06</intervention_name>
    <description>14 day dosing</description>
    <arm_group_label>GLU-06</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Generally healthy adults between 21-65 years of age&#xD;
&#xD;
          -  Body Mass Index (BMI) between 25 and ≤40&#xD;
&#xD;
          -  OGTT (75g glucola) peak value between ≥140mg/dl and ≤199 mg/dl at screening visit&#xD;
&#xD;
          -  Willingness to adhere to the requirements of the protocol, including availability for&#xD;
             follow-up visits and donation of blood samples&#xD;
&#xD;
          -  Willingness and ability to sign written informed consent&#xD;
&#xD;
          -  Women of child bearing capacity who agree to use an acceptable form of birth control&#xD;
             during the trial [i.e., oral contraception, reliable use of a double-barrier method&#xD;
             (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal&#xD;
             ligation]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active diabetes mellitus [fasting blood glucose of ≥7.0 mmol/L (≥126 mg/dL) or ≥11.1&#xD;
             mmol/L (≥200 mg/dL) after OGTT]&#xD;
&#xD;
          -  Current coronary artery/ cardiovascular disease or history of a cardiovascular event&#xD;
             (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary&#xD;
             artery bypass grafting, angina pectoris) or have undergone a cardiovascular&#xD;
             intervention within the past three months&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men&#xD;
             and less than 12 g/dL in women)&#xD;
&#xD;
          -  Active infection, including HIV, hepatitis, etc&#xD;
&#xD;
          -  Participants on Estrogen replacement must be on a stable dose for at least 3 months&#xD;
&#xD;
          -  Serious illness requiring ongoing medical care or medication&#xD;
&#xD;
          -  Gastrointestinal disorders or prior gastrointestinal surgeries (including gastric&#xD;
             bypass or lap-band) that might cause complications or influence motility or satiety&#xD;
             (e.g.,diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal&#xD;
             narrowing or obstruction, difficulty swallowing)&#xD;
&#xD;
          -  Any congenital spinal cord deformities or traumatic spinal cord injuries&#xD;
&#xD;
          -  Uncorrected hypothyroidism&#xD;
&#xD;
          -  Other significant metabolic endocrine disease&#xD;
&#xD;
          -  Active liver disease or liver function impairment as evidenced by a history of liver&#xD;
             disease or liver enzyme elevations &gt;three times the upper limit of normal&#xD;
&#xD;
          -  Current cancer&#xD;
&#xD;
          -  Significant kidney disease (calculated by eGFR &lt;60 mL/min)&#xD;
&#xD;
          -  History or clinical manifestations of significant metabolic, hepatic, renal,&#xD;
             hematological, pulmonary, cardiovascular, gastrointestinal, urological,&#xD;
             neurological,or psychiatric disorders which in the opinion of the investigator would&#xD;
             be expected to interfere with the study or increase risk to the subject&#xD;
&#xD;
          -  Use of anticoagulants such as warfarin&#xD;
&#xD;
          -  Use of medications that might affect weight or food absorption (e.g.,&#xD;
             diuretics,glucocorticoids, anorexigenic agents, Orlistat, laxatives)&#xD;
&#xD;
          -  Treatment within the previous 6 months with any medication that is known to affect&#xD;
             glucose levels (such as insulin with or without an amylin analogue,&#xD;
             sulfonylureas,meglitinides, biguanide metformin, thiazolidinediones, alpha-glucosidase&#xD;
             inhibitors,oral dipeptidyl-peptidase-4 inhibitor, Sitagliptin, Incretin mimetic)&#xD;
&#xD;
          -  Regular use of natural health products or dietary supplements known to affect glucose&#xD;
             levels (such as chromium, zinc, fenugreek, cinnamon). If the participant agrees to&#xD;
             stop taking these products 14 days prior to study entry and for the duration of the&#xD;
             study, they can participate in the study&#xD;
&#xD;
             o Any other natural health products or dietary supplements, with the exception of&#xD;
             vitamins and minerals with dose of &lt; 600 mg/day of vitamin E and containing no vitamin&#xD;
             K. Natural health products or dietary supplements include products such as, but not&#xD;
             limited to, Echinacea, Ginseng, St. John's Wort, Gingko, Glucosamine, Fish Oil&#xD;
             supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the&#xD;
             form of pills, extracts, capsules, or tablets. If the participant agrees to stop&#xD;
             taking these products 14 days prior to study entry and for the duration of the study,&#xD;
             they can participate in the study&#xD;
&#xD;
          -  Vegan or Vegetarian&#xD;
&#xD;
          -  Pregnant or lactating women, or intending to become pregnant&#xD;
&#xD;
          -  Known allergy to any ingredient in the study product&#xD;
&#xD;
          -  Any significant auto-immune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Udani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicus Research LLC/Staywell Research LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staywell Research LLC</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>pre-diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

